EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CervoMed's enterprise value is $156.56 Mil.
CervoMed's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, CervoMed's EV-to-Revenue for today is .
The historical rank and industry rank for CervoMed's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of CervoMed was 3629.43. The lowest was 13.86. And the median was 26.97.
CRVO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.215 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-22), CervoMed's stock price is $19.44.
CervoMed's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, CervoMed's PS Ratio for today is .
CervoMed EV-to-Revenue Historical Data
The historical data trend for CervoMed's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CervoMed's EV-to-Revenue
For the Biotechnology subindustry, CervoMed's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CervoMed's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CervoMed's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CervoMed's EV-to-Revenue falls into.
CervoMed's current Enterprise Value is $156.56 Mil.
CervoMed's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CervoMed's share price for today is $19.44.
CervoMed's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CervoMed EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CervoMed's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRVO has been successfully added to your 